NCT06490068View on ClinicalTrials.gov

Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

LTC004+Toripalimab

"LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W."

Trial Locations (1)

Unknown

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER